AdBoards

A large multi-national diagnostic company was interested in understanding the market landscape and potential strategy for the decentralization of NIPT in the U.S.

A healthcare technology startup wanted to conduct an assessment of potential go-to-market strategies for their AI analytical patient recruitment tool

A top-10 diagnostics company wanted to gauge preparedness and reactions to implementation of IVDR, and how that would impact a potential new product

A large pharma new to precision oncology wanted to understand the processes and requirements to ensure that their novel CDx was included into diagnostic guidelines globally

A top-10 biopharma wanted to assess how the biomarker testing and treatment landscape would change, and the potential impact on the use of their drug, in response to a recent approval of a new competing cancer therapy approved in earlier lines of treatment

A global healthcare investment firm wanted to perform a commercial due diligence (CDD) prior to investment in a company producing a novel handheld diagnostic.